Baseline demographics of the cohort
| Etanercept | Infliximab | Adalimumab | Rituximab | Tocilizumab | Certolizumab | |
| Number exposed (n) | 8630 | 4908 | 7818 | 5101 | 2174 | 1446 |
| Years of follow-up | 15 314 | 8829 | 13 071 | 5910 | 1963 | 1685 |
| Mean age in years (SD) | 56 (12) | 56 (12) | 56 (12) | 60 (12) | 57 (12) | 56 (12) |
| Female (%) | 77.5 | 76.8 | 77.4 | 78.6 | 79.6 | 76.1 |
| Mean disease duration: years (SD) | 13 (9) | 13 (9) | 13 (9) | 16 (10) | 1510 | 11 (9) |
| Mean DAS28 (SD) | 6.5 (1.1) | 6.6 (1.0) | 6.4 (1.1) | 6.4 (1.1) | 6.1 (1.3) | 5.9 (1.1) |
| Mean HAQ (SD) | 2.0 (0.6) | 2.1 (0.6) | 1.9 (0.6) | 2.0 (0.6) | 1.9 (0.6) | 1.6 (0.8) |
| Steroid user (%) | 43.6 | 46.7 | 39.4 | 42.5 | 38.6 | 28.5 |
| Current smoker (%) | 21.3 | 22.1 | 22.7 | 22.4 | 22.6 | 21.4 |
| Seropositive (%) | 64.0 | 66.3 | 63.0 | 67.3 | 61.4 | 58.4 |
| DMARD therapy | ||||||
| Methotrexate (%) | 48.5 | 79.0 | 55.7 | 59.0 | 58.2 | 63.4 |
| Sulfasalazine (%) | 15.4 | 13.9 | 18.6 | 14.1 | 14.0 | 27.4 |
| Leflunomide (%) | 8.8 | 6.7 | 10.0 | 8.7 | 7.3 | 9.0 |
| Hydroxychloroquine (%) | 11.3 | 8.8 | 13.3 | 11.5 | 15.6 | 29.6 |
| Number of drugs | ||||||
| 0–5 drugs (%) | 51.4 | 46.9 | 49.8 | 45.9 | 44.5 | 48.1 |
| 6–10 drugs % | 42.0 | 49.3 | 43.6 | 45.6 | 44.5 | 45.1 |
| More than 10 drugs (%) | 6.6 | 4.6 | 6.6 | 8.5 | 11.0 | 6.8 |
| Comorbidities | ||||||
| Asthma (%) | 11.2 | 9.9 | 10.5 | 11.8 | 13.7 | 12.1 |
| COPD (%) | 5.5 | 4.6 | 4.4 | 6.0 | 5.0 | 4.1 |
| Diabetes (%) | 6.1 | 5.0 | 6.0 | 6.6 | 7.6 | 6.1 |
COPD, chronic obstructive pulmonary disease; DAS28, Disease Activity Score 28; DMARD, disease-modifying antirheumatic drugs; HAQ, Health Assessment Questionnaire.